Ductal carcinoma in situ of the breast

被引：43
作者：
Silverstein, MJ [1 ]
机构：
[1] Univ So Calif, Norris Canc Ctr, Harold E & Henrietta C Lee Breast Ctr, Los Angeles, CA 90033 USA
来源：
ANNUAL REVIEW OF MEDICINE | 2000年 / 51卷
关键词：
DCIS; breast cancer; noninvasive breast cancer; in situ breast cancer; minimal breast cancer; ductal carcinoma in situ;
D O I：
10.1146/annurev.med.51.1.17
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Ductal carcinoma in situ of the breast is a heterogeneous group of lesions with diverse malignant potential. It is the most rapidly growing subgroup in the breast cancer family; it is projected that more than 39,000 new cases will be diagnosed in the United States during 1999. Most new cases are nonpalpable and are discovered mammographically. Treatment is controversial and ranges from excision only, to excision with radiation therapy, to mastectomy. Genetic changes routinely precede morphologic evidence of malignant transformation. Medicine must learn how to recognize these genetic changes, exploit them, and in the future, prevent them.
引用
收藏
页码：17 / 32
页数：16
相关论文
共 47 条
  • [1] DNA PLOIDY IN INTRADUCTAL BREAST CARCINOMAS
    AASMUNDSTAD, TA
    HAUGEN, OA
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (09) : 956 - 959
  • [2] Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
    Albertini, JJ
    Lyman, GH
    Cox, C
    Yeatman, T
    Balducci, L
    Ku, NN
    Shivers, S
    Berman, C
    Wells, K
    Rapaport, D
    Shons, A
    Horton, J
    Greenberg, H
    Nicosia, S
    Clark, R
    Cantor, A
    Reintgen, DS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22): : 1818 - 1822
  • [3] ASHIKARI R, 1971, CANCER, V28, P1182, DOI 10.1002/1097-0142(1971)28:5<1182::AID-CNCR2820280515>3.0.CO
  • [4] 2-H
  • [5] RELATIONSHIP BETWEEN C-ERBB-2 IMMUNOREACTIVITY AND THYMIDINE LABELING INDEX IN BREAST-CARCINOMA INSITU
    BARNES, DM
    MEYER, JS
    GONZALEZ, JG
    GULLICK, WJ
    MILLIS, RR
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) : 11 - 17
  • [6] IMMUNOHISTOCHEMICAL DEMONSTRATION OF C-ERBB-2-PROTEIN IN MAMMARY DUCTAL CARCINOMA INSITU
    BARTKOVA, J
    BARNES, DM
    MILLIS, RR
    GULLICK, WJ
    [J]. HUMAN PATHOLOGY, 1990, 21 (11) : 1164 - 1167
  • [7] NONINVASIVE DUCTAL CARCINOMA OF THE BREAST - THE RELEVANCE OF HISTOLOGIC CATEGORIZATION
    BELLAMY, COC
    MCDONALD, C
    SALTER, DM
    CHETTY, U
    ANDERSON, TJ
    [J]. HUMAN PATHOLOGY, 1993, 24 (01) : 16 - 23
  • [8] GROWTH-FACTORS IN BREAST-CANCER
    DICKSON, RB
    LIPPMAN, ME
    [J]. ENDOCRINE REVIEWS, 1995, 16 (05) : 559 - 589
  • [9] Incidence of and treatment for ductal carcinoma in situ of the breast
    Ernster, VL
    Barclay, J
    Kerlikowske, K
    Grady, D
    Henderson, IC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12): : 913 - 918
  • [10] Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
    Fisher, B
    Dignam, J
    Wolmark, N
    Wickerham, DL
    Fisher, ER
    Mamounas, E
    Smith, R
    Begovic, M
    Dimitrov, NV
    Margolese, RG
    Kardinal, CG
    Kavanah, MT
    Fehrenbacher, L
    Oishi, RH
    [J]. LANCET, 1999, 353 (9169) : 1993 - 2000
12345